New COVID-19 drug shows greater promise against resistant viral strains
Rutgers Health researchers have developed an oral antiviral drug candidate for COVID-19 that could overcome major limitations ...
The Munich Eye8 小时
Promising New Oral Antiviral Drug Targets Resistant COVID-19 Strains
Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.
The Washington Post1 个月
Paxlovid may not reduce hospitalization risk for vaccinated older adults
Paxlovid, the five-day antiviral treatment for covid, may not reduce the risk of covid-related hospitalizations and all-cause deaths in vaccinated older adults, a new study suggests. Paxlovid ...
pharmaphorum5 天
Six months after authorization, what do we know about Paxlovid?
It has now been over six months since the FDA authorized Paxlovid in December 2021 “for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older ...
来自MSN1 个月
Paxlovid shows no clear benefit in preventing hospitalization, death among vaccinated seniors
Since its emergency authorization in late 2021, Paxlovid has been a cornerstone of COVID-19 treatment. The medication combines two antiviral drugs—nirmatrelvir and ritonavir—that work together ...
Wall Street Journal8 个月
Biden Continues Paxlovid Treatment for Covid-19
O’Connor said the Paxlovid treatment would continue and the president would keep working. The White House said Wednesday that Biden, 81 years old, had tested positive for Covid-19. He is ...